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Abstract 34	
This investigation aimed to explore the effects of inert sugar free drinks described as 35	
either ‘performance enhancing’ (placebo) or ‘fatigue inducing’ (nocebo) on peak 36	
minute power (PMP;W) during incremental arm crank ergometry (ACE).  Twelve - 37	
healthy, non - specifically trained individuals volunteered to take part. A single blind 38	
randomized controlled trial with repeated measures was used to assess for differences 39	
in PMP;W and oxygen uptake, heart rate, minute ventilation, respiratory exchange 40	
ratio, and subjective reports of local (LRPE) and central (CRPE) ratings of perceived 41	
exertion, between three separate, but identical ACE tests. Participants were required 42	
to drink either 500ml of a ‘sports performance’ drink (placebo), a ‘fatigue inducing’ 43	
drink (nocebo), or water prior to exercise. The placebo caused a significant increase in 44	
PMP;W, and a significant decrease in LRPE compared to the nocebo (p=0.01; 45	
p=0.001) and water trials (p=0.01). No significant differences in PMP;W between the 46	
nocebo and water were found. However, the nocebo drink did cause a significant 47	
increase in LRPE (p=0.01).  These results suggest that the time has come to broaden 48	
our understanding of the placebo and nocebo effect and their potential to impact 49	
sports performance. 50	
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Introduction  55	
The placebo effect in sport has only become a subject of regular research enquiry in 56	
the last 10 to 15 years. Despite this slow start, several studies have observed 57	
significant increases in endurance (Clark, Hopkins, Hawley and Burke, 2000) and 58	
strength performance (Maganaris, Collins and Sharp, 2000; Kalasountas, Reed and 59	
Fitzpatrick, 2007) as a result of ingesting a substance with no inherent ability to 60	
produce such a positive effect.  61	
Despite suggestions of its existence in sports science, less is known about the nocebo 62	
effect (Beedie and Foad, 2009), defined as ‘the undesirable effects an individual 63	
experiences after ingesting an inert substance’. However, it is axiomatic to propose 64	
that the nocebo effect may be just as relevant to sports performance (Maganaris et al., 65	
2000; Kalasountas et al., 2007).  For example, Maganaris et al. (2000) and 66	
Kalasountas et al. (2007) reported significant decreases in performance when subjects 67	
were told that their improvements in weightlifting were the result of a sham anabolic 68	
steroid. Such a suggestion assumes the nocebo effect is simply reversing a positive 69	
outcome, which may underestimate its true potential to negatively impact 70	
performance if studied in isolation.  71	
Testing this hypothesis, Beedie, Coleman and Foad (2007) observed a trend towards 72	
reduced speed in consecutive sprint trials in a group that held a negative belief about 73	
an inert substance. In comparison they found a significant linear trend of greater 74	
speed with each successive experimental trial in a group that had been informed that 75	
the same substance enhanced performance. Compared to mainstream medicine an 76	
understanding of the placebo/nocebo remains in its infancy. However, a greater 77	
understanding of the placebo/nocebo effect, and their application to various sports and 78	
exercise modalities will supplement current understanding of these factors reportedly 79	
influencing athletic performance.  Prior research and theory from the pain sciences 80	
suggest that expectations influence the placebo/nocebo effect (Stewart-Williams and 81	
Podd, 2004; Pollo et al., 2001; Fillmore and Vogel-Sprott, 1992). Illustrating this 82	
point, Clark et al. (2000) reported the greatest changes in power during a 40km cycle 83	
time trial, in a group that were told their performance would be increased by 84	
carbohydrate administration, regardless of whether they eventually received 85	
carbohydrate or placebo.  86	
 87	
Contrary to this, ambiguity surrounding the proposed treatment may produce results 88	
that are incongruent with expectation (Foad, Beedie and Coleman, 2008). More 89	
specifically, Foad et al. (2008) reported that the effects of caffeine were greatest when 90	
participants believed that they had not ingested caffeine as opposed to when they 91	
believed they had. The mere presence of potential placebo and/or a placebo design 92	
made individuals question treatment allocation and thus had a contradictory effect on 93	
the anticipated outcome. Despite the link between expectation and the placebo effect, 94	
few studies have assessed this experimentally in the sports science domain (Pollo, 95	
Carlino and Benedetti, 2008).  A better understanding here may help to clarify the 96	
relationship between the effect an individual expects to experience, and the actual 97	
experience itself.  A meta-anlysis by Berdi, Koteles, Szabo, and Bardos (2011) has 98	
established that further research is needed to determine the importance of the placebo 99	
effect on sports performance and that a more balanced placebo design is required 100	
along with comparing a no treatment group.  Therefore, the current investigation 101	
aimed to explore the effects of inert sugar free drinks described either as ‘performance 102	
enhancing’ (Sports performance drink - placebo) or ‘fatigue inducing’ (nocebo) or 103	
plain water on peak minute power (PMP;W) during an incremental arm crank 104	
ergometry (ACE) test to volitional exhaustion. This dynamic has not been explored 105	
previously and as incremental tests are used extensively in applied and clinical 106	
settings it is a valid predictor of performance and health respectively (Bassett and 107	
Howley, 2000).  It was hypothesised that the sports performance and fatigue inducing 108	
drink would significantly increase and decrease PMP;W respectively, compared to a 109	
comparison test using water.   110	
 111	
 112	
Methods 113	
 114	
Participants 115	
Twelve, healthy, non-specifically trained, able-bodied male individuals volunteered to 116	
take part in the study (mean ±SD age: 25.3 ± 4.4 years; weight: 80.5 ± 16.9 kg; 117	
height: 178.8 ± 4.4 cm).  Participants volunteered to take part on the basis that they 118	
would received the outcome of the study but no financial incentive was provided. 119	
Participants were injury free at the time of data collection and provided written 120	
informed consent.  University Ethics Committee approval for the study’s 121	
experimental procedures was obtained and followed the principles outlined in the 122	
Declaration of Helsinki.   123	
 124	
Design:  125	
 126	
Participants were required to perform three separate (one week apart), incremental 127	
tests using a Monark arm crank ergometer (Monark Inc, London UK) to determine 128	
PMP;W.  Thirty minutes prior to each test, participants were required to drink either 129	
500ml of water, or the same volume of a ‘sports performance’ (placebo) or ‘fatigue 130	
inducing’ drink (nocebo). These drinks were in fact identical commercial sugar - free 131	
drinks that had no known physiological effect on performance. The study was 132	
performed in a randomized cross over design and was single blinded.  133	
 134	
Prior to the relevant test, a standardized written script was handed to the participant’s. 135	
These highlighted how the drinks worked to increase (sports performance drink) or 136	
decrease (fatigue inducing drink) PMP;W. Participants were told that the water trial 137	
was being used as a comparison.  138	
 139	
 140	
Procedures: 141	
 142	
 143	
A ramp protocol was used whereby power output (watts) increased every two minutes 144	
(Price et al., 2011; Smith et al., 2001). Participants initially exercised for two minutes 145	
at 0W. After this, the workload increased to 50W, and then by 20W every two 146	
minutes. Participants were required to complete the test using a constant speed of 70 147	
rev. min-1 until volitional exhaustion.  148	
 149	
PMP;W was calculated using the value(s) of the workload experienced during the 150	
final minute of the test. If a participant performed their final workload at 150W for a 151	
minute, their PMP was 150W. However if a participant performed at different 152	
workloads, the calculation by Smith et al. (2004) was used to determine PMP;W.  153	
 154	
Oxygen consumption (VO2) respiratory exchange ratio (RER), carbon dioxide 155	
production (VCO2) and minute ventilation were analysed using an online breath-by-156	
breath analysis system (Cosmed Quark b2 metabolic analyse-gas analysis) and 157	
averaged over the final 15 seconds of each workload, and over the final 15 seconds of 158	
the test for peak responses. Heart rate (HR) was monitored using a heart rate monitor, 159	
and measured at the same intervals (Price, Bottoms, Smith and Nicholettos, 2011).  160	
 161	
Fingertip blood samples were collected at volitional exhaustion and analysed for 162	
blood lactate concentration (Analox GM7, Surrey, UK). Ratings of perceived exertion 163	
for local working muscles (LRPE) and cardio-respiratory (CRPE) components of 164	
effort perception (Borg Scale) were recorded during the last 15 seconds of each 165	
exercise stage and at volitional exhaustion (Price et al., 2011).  166	
  167	
After the third test, participants were asked to identify (using a Likert scale from 1 to 168	
10) the degree to which they expected the sports performance drink would positively 169	
impact their performance (1 being not at all, 5 to some extent and 10 being very much 170	
so), and the degree to which they expected the nocebo drink would decrease their 171	
performance (1 being very much so, 5 to some extent and 10 being not at all). 172	
Following this, they were informed about the true nature of the experiment and why 173	
deception was a fundamental component. 174	
 175	
Statistical analysis  176	
All data was analysed using SPSS version 20.0. The Shapiro-Wilk statistic confirmed 177	
that the normal distribution assumption was met for all variables.  Therefore, a 178	
repeated measures one-way ANOVA was used to assess differences in PMP:W 179	
between trials, post blood lactate values, and expectation scores (Likert scale).  A 180	
two-way ANOVA for repeated measures was used to assess the main effect of time, 181	
group, and time - group interactions for physiological variables: heart rate, VO2, 182	
VCO2, RER, VE, and subjective ratings of central and local RPE values. Appropriate 183	
post-hoc analyses were conducted using a Bonferroni correction to control for type I 184	
error. Partial effect sizes were calculated using an η2. Spearman’s rank correlation co-185	
efficients were used to explore the relationship between the extent to which the 186	
participants expected (likert score) the two drinks would increase (placebo)/ decrease 187	
(nocebo) their performance, and how their PMP;W subsequently increased/ decreased 188	
compared to the water trial. Data	are	presented	as	mean		 standard	deviation	 in	189	
tables	and	figures.	Significance	was	set	at	p<0.05. 190	
 191	
 192	
Results  193	
PMP;W 194	
 195	
Ten out of 12 participants improved on the placebo trial compared to the water trial 196	
(Table 1), whereas only 5 out of 12 participants produced a lower PMP;W on the 197	
nocebo trial compared to the water trial.   198	
 199	
***Table 1 near here*** 200	
 201	
A significant difference in PMP;W was found between the three conditions (F2, 22 202	
=5.8: p= .001, η2= .347, with the highest PMP;W values occurring in the placebo trial 203	
(Figure 1). Post - hoc analyses demonstrated a significant increase in PMP;W using 204	
the placebo compared to water (p= .013), and the nocebo (p= .044). No significant 205	
difference in PMP; W was found between the nocebo and water (p= 1.00). 206	
 207	
Physiological measurements 208	
A significant increase in LRPE with exercise intensity was observed (main effect of 209	
time (F5, 30 =130.0: p <.001, η2= .956). Furthermore, significant differences in LRPE 210	
values between the conditions (main effect of condition (F2, 12 =4.81: p =.03, η2= 211	
.445).  Post - hoc analyses demonstrated significantly lower LRPE for placebo 212	
compared to water (p =.004), and significantly greater LRPE values for nocebo 213	
compared to water (p = .01), and finally significantly higher values for nocebo 214	
compared to placebo (p = .001; Table 2).  There was no significant interaction 215	
between condition and time (F10, 60 =1.76: p = .09, η2= .270). 216	
 217	
HR, VO2, VCO2 RER and subjective scores of central ratings of perceived exertion 218	
increased significantly with exercise intensity as they all demonstrated significant 219	
main effects for time (F5, 15 =39.0: p < .001, η2= .929, F5, 20 =33.4: p < .001, η2= .893, 220	
F5, 20 =9.5: p < .001, η2= .759, F5, 15 = 11.99: p < .001, η2= .800 and F5, 25 =60.4: p < 221	
.001,  η2= .930 respectively). However, no significant condition and time * condition 222	
interactions were found. Post blood lactate levels did not differ between the three 223	
conditions (F2, 22 = 1.897: p = .174, η2= .147; Table 2).  224	
 225	
***Table 2 near here*** 226	
 227	
A significant difference between the three Likert scores (expectation) was found (F2,22 228	
= 14.2: p < .001, η2= .563). Post hoc tests revealed significantly greater scores for 229	
placebo compared to water (p < .001), and for nocebo compared to water (p < .001), 230	
with no significant difference observed between the placebo and nocebo (p = .80).   231	
 232	
 233	
Spearman’s rank correlation co-efficients revealed a significant correlation (rho= 0.85 234	
; p < .001) between individuals who had the greatest increase in PMP;W (compared to 235	
water) and those who had the highest expectation of the placebo drink (Likert). 236	
Similarly, a significant weak correlation was found between individuals who had the 237	
largest decrease in performance (compared to water) and individuals with the highest 238	
expectation of the nocebo drink (Figures 1 and 2 respectively).  239	
 240	
***Figures 1 and 2 near here*** 241	
242	
Discussion 243	
Consistent with the hypothesis, the current investigation demonstrated a significant 244	
increase in PMP;W when participants ingested a placebo drink compared to water. 245	
Furthermore, a significant decrease in LRPE compared to water and nocebo was 246	
observed. Consequently, participants increased their power output, whilst 247	
simultaneously reporting less discomfort in their arms.  248	
 249	
These data add to an increasing number of studies that have reported improvements in 250	
performance as a result of ingesting a placebo aid. The percentage increases in 251	
performance here (6.3%; percentage increase in PMP;W compared to the water and 252	
nocebo trial) are both lower (Pollo et al., 2008; Kalasountas et al., 2007; Ariel and 253	
Saville, 1972) and higher than values previously recorded (Foad et al., 2008; Beedie 254	
et al., 2007; McClung and Collins, 2007; Beedie et al., 2006; Clark et al., 2000; 255	
Maganaris et al., 2000). However, methodological variances between the studies, 256	
including the mode of exercise and its outcome measure, and the duration of the study 257	
make direct comparisons difficult. The present study used a water trial as a no 258	
treatment group to more accurately assess the extent of the placebo effect as 259	
suggested by Berdi et al. (2011). The collective data do suggest that the placebo can 260	
exert its effect across several exercise modalities and protocols of different durations.  261	
 262	
Contrary to the hypothesis the nocebo drink failed to cause a significant decrease in 263	
performance. This asymmetry between the placebo and nocebo may be due to 264	
discrepancies in the participant’s appreciation of the two drinks. That is, participants 265	
better understood that a drink could increase, rather than decrease performance. 266	
Statistical tests suggested that there was no significant difference in the expectation 267	
assigned to the two drinks (Likert scale). This finding may highlight a possible 268	
limitation of the Likert scale and it may not be sensitive enough to determine 269	
differences, compared to qualitative equivalents. In addition, the likert scale was 270	
given after the test and may therefore not completely reflect their expectation prior to 271	
the test. In future the scale should be presented prior to the test to more accurately 272	
measure the expectation of the drink.  It may also be reasonable to suggest that a 273	
fatigue inducing drink may not be the best method of activating a nocebo response.  274	
 275	
It is important to highlight an observation from the current investigation that provides 276	
evidence for the nocebo. Evidence for a nocebo response was the response of LRPE 277	
with the nocebo causing a significant increase in LRPE compared to water and the 278	
placebo. These data add to previous data that suggest that expectations alter somatic 279	
perception (Caspi and Bootzin, 2002; Lundh, 1987; Ross and Olson, 1981) by causing 280	
individuals to selectively attend to an increase or decrease in their symptoms (seen in 281	
the present study as an increase or decrease in LRPE).  282	
  283	
The present study used an incremental VO2 peak test. This design was chosen because 284	
it is a valid and objective test of performance in the exercise domain (Bassett and 285	
Howley, 2000). The potential to impact performance during this mode of exercise has 286	
implications for a number of different individuals such as kayakers. Due to the 287	
smaller muscle mass of the arms in comparison to lower body exercise, a different 288	
response may have been expected to that previously shown with lower body exercise.  289	
The current study used well - defined objective physiological measures to identify a 290	
maximal effort to limit potential suggestions that the ‘placebo effect’ was simply 291	
attributable to participants trying harder (Kalasountas et al., 2007).  292	
 293	
The current investigation used a Likert scale, in order to identify the relationship 294	
between the expectation of a change in performance and those individuals with who 295	
had the greatest change in PMP;W. This assessment tool was easy to use, and 296	
significant correlations were found between individuals with the highest expectations 297	
of the placebo and nocebo drink and individuals who subsequently had the greatest 298	
changes in PMP; W compared to the water trial.  However, this scale failed to identify 299	
any individual factors that may have increased an individual’s expectations of the two 300	
drinks, possibly because it was presented after the test rather than prior to the test. 301	
This may be particularly important since not all participants experienced a placebo/ 302	
nocebo effect. Qualitative data may have provided more information about individual 303	
experiences, and should feature in future research (Mengshoel, 2012).  304	
 305	
These data, together with previous work, suggests that the placebo and nocebo have 306	
the capacity to influence sport performance. Further work should be focused on how 307	
coaches and clinicians can develop techniques to harness the placebo, whilst avoiding 308	
a potential nocebo response. From a theoretical standpoint, further research into the 309	
placebo/nocebo may also broaden our understanding of how the brain governs 310	
peripheral processes that influence sports performance. For example, it has been 311	
suggested that fatigue during exercise involves a complex interaction between a 312	
number of peripheral physiological systems and the brains evaluation of the 313	
‘exercising body’ (Gibson et al., 2006; Lambert, Gibson and Noakes, 2005). Thus, 314	
whilst peripheral factors such as metabolite accumulation are important, the brain 315	
orchestrates the final decision, based on all relevant factors, including for example, 316	
the knowledge that a drink has been consumed that is ‘sport enhancing’. This may 317	
manifest in a situation like that seen in the current investigation where an increase in 318	
PMP’;W is observed despite there being no significant difference between the groups 319	
for objective physiological markers. 320	
 321	
In conclusion, the current investigation reported a significant increase in PMP; W 322	
together with a decrease in LRPE, following the ingestion of an inert ‘sports 323	
performance’ drink. The current study failed to report a significant nocebo effect on 324	
PMP;W. However, a significant increase in LRPE was observed compared to water 325	
and the placebo drink. These results suggest that the time has come to broaden our 326	
understanding of the placebo and nocebo effect and their potential to impact sports 327	
performance. Future work should supplement quantitative measures of physical 328	
function, with qualitative interviews to better understand the factors that influence an 329	
individual’s response.  More specifically, participants can be asked to report their 330	
sensations during the placebo and nocebo conditions.  This data can then be 331	
referenced against objective physiological measures to provide a wider picture of the 332	
human response to the consumption of performance enhancing or inhibiting drinks.  333	
Ultimately, a better understanding here may enable clinicians and coaches to develop 334	
techniques to harness the placebo and or avoid the nocebo and with it open a 335	
potentially very large and important door.  336	
 337	
 338	
 339	
 340	
 341	
 342	
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Tables: 433	
434	
Table 1: PMP;W values for the three trials * significant difference between tests (p 435	
<0.05). 436	
Participant 
Water 
PMP;W (watts)  
Nocebo 
PMP;W (watts)   
Placebo 
PMP;W (watts) 
1 138 136 148 
2 130 130 130 
3 145 130 155 
4 90 90 110 
5 110 117 114 
6 145 130 150 
7 158 145 162 
8 153 150 158 
9 130 150 150 
10 110 113 110 
11 125 125 130 
12 130 130 130 
Mean  SD 130  20 12917 13719* 
	437	
438	
Table 2. Mean ±SD for the physiological variables. *+#denotes significant 439	
differences.	440	
	441	
	442	
	443	
	444	
	445	
	446	
 447	
 448	
 449	
 450	
 451	
 452	
 453	
 454	
 455	
 456	
457	
 Peak Value 
(water) 
Peak Value 
(Nocebo) 
Peak Value 
(placebo) 
VO2 (l.min-1) 2.95  0.99 2773  397 2.62  0.98 
VCO2 (l.min-
1) 
3.72  0.13 2.67  0.88 3.23  0.12 
RER   1.19  0.1 1.14  0.1 1.29  0.1 
VE (l.min-1) 120  28  127  15 123  4 
HR 
(beats.min-1) 
168  16  159  21  167  20  
CRPE (borg 
scale) 
18  2 16  2 17  2 
LRPE (borg 
scale) 
19 ± 1*# 20 ± 1*+ 18 ± 1#+ 
Blood lactate 
(mmol) 
9.0  2.5 8.2  2.1 10.0  2.8  
List of Figures: 458	
Figure 1: Relationship between the increase in PMP:W (placebo drink compared to 459	
the water trial) and the expectation of an increase in performance (Likert score) (r 460	
=0.95; p<0.001) 461	
Figure 2: Relationship between the decrease in PMP;W (nocebo drink compared to 462	
the water trial) and the expectation of a decrease in performance (Likert score) 463	
(r=0.97; p <0.001) 464	
 465	
 466	
